Cargando…
Role of the EGFR-KDD mutation as a possible mechanism of acquired resistance of non-small cell lung cancer to EGFR tyrosine kinase inhibitors: A case report
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are currently considered as the standard therapy for patients with advanced non-small cell lung cancer (NSCLC) who have EGFR-activating mutations. However, despite an initially profound response to these drugs, these patients ul...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
D.A. Spandidos
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719261/ https://www.ncbi.nlm.nih.gov/pubmed/34987800 http://dx.doi.org/10.3892/mco.2021.2463 |